LivaNova Outlines Enterprising Growth Strategy with Focus on Epilepsy, Cardiopulmonary, and Sleep Apnea
LivaNova PLC (Nasdaq: LIVN) unveiled a thorough strategic roadmap and long-range financial plan at its 2025 Investor day, signaling confidence in its ability to achieve notable growth and deliver value to stakeholders. The company, a market leader in medical technology, detailed plans to capitalize on existing strengths while expanding into promising new markets.
Strategic Roadmap and Financial Targets
According to a company release, LivaNova’s leadership team is focused on revitalized innovation and operational excellence.”We are confident in our ability to deliver on the targets we outlined today,” stated Vladimir Makatsaria, Chief Executive Officer of LivaNova.”LivaNova’s talented team is focused on a revitalized innovation strategy and operational excellence.”
The company’s market-leading Cardiopulmonary business, operating within a $2 billion global market, will focus on capitalizing on the continued replacement cycle of Essenz™, gaining market share with consumables, and leveraging recurring revenue streams from software and service attachments. These efforts are projected to generate mid-to-high single-digit revenue CAGR and expand adjusted operating margins by over 300 basis points.
In the Drug-Resistant Epilepsy market, where significant unmet needs remain, LivaNova anticipates continued profitable growth. This will be supported by real-world evidence from the CORE-VNS clinical study, the launch of a connected care platform (estimated in 2026) and a Bluetooth-enabled implantable pulse generator (estimated in 2027), and expanded global access and reimbursement. The company is targeting mid-single-digit revenue CAGR and approximately 200 basis points of adjusted operating income margin expansion by 2030.
Obstructive Sleep Apnea: A Key Growth Driver
A significant component of LivaNova’s future growth is its entry into the large and underpenetrated OSA market with its proximal hypoglossal nerve stimulation (p-HGNS) technology. The company highlighted the robust clinical evidence supporting its PolySync Algorithm™, which utilizes a six-electrode design for targeted nerve activation and improved patient response.
LivaNova intends to independently commercialize its OSA product in 2027, retaining full control over pricing, positioning, and customer relationships. The company projects OSA to generate $200 million to $400 million in revenue by 2030, with an adjusted operating income margin exceeding 25% and achieving break-even status by 2029.
Challenging-to-Treat Depression: Upside Potential
While not currently factored into long-range financial projections, LivaNova continues to pursue coverage with the U.S. Centers for Medicare & Medicaid Services (CMS) for its Difficult-to-Treat Depression therapy. Securing CMS coverage would represent a significant upside prospect, building on the company’s neuromodulation platform.
Investor Resources
The presentation and webcast replay from the investor event will be available within 24 hours at www.livanova.com/events.
About LivaNova
LivaNova PLC is a global medical technology company with nearly five decades of experience, dedicated to changing the trajectory of lives through innovative solutions in neurological and cardiac conditions. Headquartered in London and operating in over 100 countries with approximately 3,000 employees, livanova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, visit www.livanova.com.
Forward-Looking Statements
This release contains forward-looking statements regarding the company’s goals, beliefs, and plans. Actual results may differ materially due to various factors, as detailed in the company’s filings with the Securities and Exchange Commission. LivaNova does not undertake any obligation to update this information.
